Manufacturer or GPO Program year 2025 Source: CMS Open Payments

R-Pharm US LLC

NJ, United States

CMS manufacturer 100000136422

Open in the dashboard

General payments

$87,342

154 payments

Research payments

$313,416

6 payments

Ownership & investment interest

$0

None reported

Through program year 2025, R-Pharm US LLC reported paying $87,342 in general payments and $313,416 in research payments to U.S. physicians, teaching hospitals and other recipients.

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

8 rows
Year Kind Amount Payments
2025 General $601 10
2024 General $588 7
2022 General $141 3
2021 General $16 1
2021 Research $3,900 1
2020 General $13,575 23
2020 Research $309,516 5
2019 General $72,421 110

Breakdown

Top recipients General payments · program year 2025
  1. Alexander Olawaiye Gynecologic Oncology · Pittsburgh, PA $320 2 payments
  2. Alessandro Santin Obstetrics & Gynecology · New Haven, CT $93 1 payment
  3. Adam Brufsky Pittsburgh, PA $40 1 payment
  4. Mario Leitao Gynecologic Oncology · New York, NY $32 1 payment
  5. Stephen Graves Obstetrics & Gynecology · Columbus, OH $32 1 payment
  6. Anna Curtin Obstetrics & Gynecology · Boise, ID $32 1 payment
  7. Matthew Flint New York, NY $32 1 payment
  8. Linda Vahdat Medical Oncology · Lebanon, NH $10 1 payment
  9. Rachel Layman Medical Oncology · Houston, TX $10 1 payment
Top research recipients Research payments · program year 2021
  1. Yale University $3,900 1 payment
Products the payments named General payments · program year 2025
  1. Ixempra Oncology $601 100% · 9 recipients

Each share is of this company’s general payments naming a product in 2025. A payment can name up to five products, so these amounts overlap.

Specialties paid General payments · program year 2025
  1. Gynecologic Oncology Obstetrics & Gynecology $352 67% · 2 practitioners
  2. Obstetrics & Gynecology $157 30% · 3 practitioners
  3. Medical Oncology Internal Medicine $20 4% · 2 practitioners

Each share is of this company’s general payments to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.

Where the money went General payments · program year 2025
  1. Pennsylvania $360 60% · 2 recipients
  2. Connecticut $93 15% · 1 recipient
  3. New York $64 11% · 2 recipients
  4. Ohio $32 5% · 1 recipient
  5. Idaho $32 5% · 1 recipient

The top 5 of 7 states; each share is of this company’s general payments in 2025 where a state was reported.

The top 25 states, free in the app

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $62,800 40 payments
  2. Honoraria $12,000 10 payments
  3. Food and Beverage $7,907 81 payments
  4. Travel and Lodging $4,509 22 payments
  5. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $125 1 payment
154 general · 6 research

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers of drugs, devices and biologicals, and group purchasing organisations, are required to report the payments and transfers of value they make to physicians and teaching hospitals. This page shows what this company reported.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record